Literature DB >> 12114734

Assessment of Mitotic Activity in Pituitary Adenomas and Carcinomas.

Kamal Thapar1, Yukio Yamada, Bernd Scheithauer, Kalman Kovacs, Shozo Yamada, Lucia Stefaneanu.   

Abstract

Assessment of mitotic activity represents one of the oldest and most routinely used histopathologic methods of evaluating the biological aggressiveness of human tumors. In the case of pituitary tumors, however, the relevance of this approach as a means of gauging tumor behavior remains ill-defined. In this article, the relationship between the mitotic index and biological aggressiveness of pituitary tumors was evaluated in a series of 54 pituitary adenomas and 6 primary pituitary carcinomas. All tumors were fully classified by immunohistochemistry and electron microscopy; adenomas were further stratified on the basis of their invasion status, the latter being defined as gross, operatively, or radiologically apparent infiltration of dura or bone. Mitotic figures were present in 11 tumors, 10 being either invasive adenomas or pituitary carcinomas. A significant association between the presence of mitotic figures and tumor behavior was noted, as evidenced by progressive increments in the proportion of cases expressing mitotic figures in the categories of noninvasive adenoma, invasive adenoma, and pituitary carcinoma (3.9, 21.4, and 66.7%, respectively; Fisher's exact test, two-tailed, p < 0.001). The mitotic index, however, appeared to be a less informative parameter, being extremely low in all cases (mean = 0.016% +/- 0.005 [+/- SEMI). Although the mean mitotic index in pituitary carcinomas (0.09% +/- 0.035) was significantly higher than the mean mitotic index of either noninvasive adenomas (0.002% +/- 0.002) or invasive adenomas (0.013% +/- 0.005), no practical threshold value capable of distinguishing these three groups was evident. Comparison of the mitotic index with Ki-67 derived growth fractions in these tumors revealed a significant but weak linear correlation (r = 0.41, p < 0.01). These data suggest that when, mitotic figures are present, they do provide some indication of the behavior and invasive potential of pituitary tumors. For routine diagnostic purposes, however, the discriminating power of this parameter is somewhat limited, being superseded by alternative and more informative methods of growth fraction determination such as that provided by the Ki-67 immunolabeling.

Entities:  

Year:  1996        PMID: 12114734     DOI: 10.1007/bf02739924

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   3.943


  12 in total

1.  The morphometric prognostic index is the strongest prognosticator in premenopausal lymph node-negative and lymph node-positive breast cancer patients.

Authors:  P J van Diest; J P Baak
Journal:  Hum Pathol       Date:  1991-04       Impact factor: 3.466

2.  Pathology of invasive pituitary tumors with special reference to functional classification.

Authors:  B W Scheithauer; K T Kovacs; E R Laws; R V Randall
Journal:  J Neurosurg       Date:  1986-12       Impact factor: 5.115

3.  Pathologic correlates of survival in 378 lymph node-negative infiltrating ductal breast carcinomas. Mitotic count is the best single predictor.

Authors:  F Clayton
Journal:  Cancer       Date:  1991-09-15       Impact factor: 6.860

4.  A decade of pituitary microsurgery. The Herbert Olivecrona lecture.

Authors:  C B Wilson
Journal:  J Neurosurg       Date:  1984-11       Impact factor: 5.115

5.  Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody.

Authors:  K Thapar; K Kovacs; B W Scheithauer; L Stefaneanu; E Horvath; P J Pernicone; D Murray; E R Laws
Journal:  Neurosurgery       Date:  1996-01       Impact factor: 4.654

6.  The use of antiavidin antibody and avidin-biotin-peroxidase complex in immunoperoxidase technics.

Authors:  S M Hsu; L Raine; H Fanger
Journal:  Am J Clin Pathol       Date:  1981-06       Impact factor: 2.493

7.  The pathogenesis of acromegaly. Clinical and immunocytochemical analysis in 75 patients.

Authors:  E R Laws; B W Scheithauer; S Carpenter; R V Randall; C F Abboud
Journal:  J Neurosurg       Date:  1985-07       Impact factor: 5.115

8.  Pathologic correlates of prognosis in lymph node-positive breast carcinomas.

Authors:  F Clayton; C L Hopkins
Journal:  Cancer       Date:  1993-03-01       Impact factor: 6.860

9.  The occurrence of dural invasion in pituitary adenomas.

Authors:  W R Selman; E R Laws; B W Scheithauer; S M Carpenter
Journal:  J Neurosurg       Date:  1986-03       Impact factor: 5.115

Review 10.  Role of surgery in the management of pituitary tumors.

Authors:  C B Wilson
Journal:  Neurosurg Clin N Am       Date:  1990-01       Impact factor: 2.509

View more
  12 in total

Review 1.  Malignant pituitary tumours.

Authors:  G A Kaltsas; A B Grossman
Journal:  Pituitary       Date:  1998-04       Impact factor: 4.107

Review 2.  Pediatric Pituitary Adenoma: Case Series, Review of the Literature, and a Skull Base Treatment Paradigm.

Authors:  Avital Perry; Christopher Salvatore Graffeo; Christopher Marcellino; Bruce E Pollock; Nicholas M Wetjen; Fredric B Meyer
Journal:  J Neurol Surg B Skull Base       Date:  2018-01-24

Review 3.  Pituitary carcinoma: report of an exceptional case and review of the literature.

Authors:  C Pichard; S Gerber; M Laloi; M Kujas; S Clemenceau; D Ponvert; E Bruckert; G Turpin
Journal:  J Endocrinol Invest       Date:  2002-01       Impact factor: 4.256

4.  Non-functioning pituitary carcinoma.

Authors:  Petra Nadja Elsässer Imboden; François-Xavier Borruat; Nicolas De Tribolet; Kathleen Meagher-Villemure; Alesia Pica; Fulgencio Gomez
Journal:  Pituitary       Date:  2004       Impact factor: 4.107

Review 5.  Corticotroph pituitary carcinoma: case report and literature review.

Authors:  D J Holthouse; P D Robbins; R Kahler; N Knuckey; P Pullan
Journal:  Endocr Pathol       Date:  2001       Impact factor: 3.943

6.  MAP-2 expression in the human adenohypophysis and in pituitary adenomas. An immunohistochemical study.

Authors:  Fabio Rotondo; Kenichi Oniya; Kalman Kovacs; C David Bell; Bernd W Scheithauer
Journal:  Pituitary       Date:  2005       Impact factor: 4.107

Review 7.  Best Practice No 172: pituitary gland pathology.

Authors:  J W Ironside
Journal:  J Clin Pathol       Date:  2003-08       Impact factor: 3.411

8.  Adrenocorticotropin-Producing Pituitary Carcinoma with Expression of c-erbB-2 and High PCNA Index: A Comparative Study with Pituitary Adenomas and Normal Pituitary Tissues.

Authors:  Vania Nose-Alberti; Maria Isabel S. Mesquita; Luciana C. Martin; Marcia J. Kayath
Journal:  Endocr Pathol       Date:  1998       Impact factor: 3.943

9.  Pituitary carcinoma with fourth ventricle metastasis: treatment by excision and Gamma-knife radiosurgery.

Authors:  Ki-Su Park; Jeong-Hyun Hwang; Sung-Kyoo Hwang; Sunzoo Kim; Seong-Hyun Park
Journal:  Pituitary       Date:  2014-12       Impact factor: 4.107

10.  Effect of Dopamine Agonists on Lactotroph Adenomas of the Human Pituitary.

Authors:  Lucia Stefaneanu; Kalman Kovacs; Bernd W. Scheithauer; George Kontogeorgos; Darren L. Riehle; Thomas J. Sebo; David Murray; Sergio Vidal; Ami Tran; Michael Buchfelder; Rudolf Fahlbusch
Journal:  Endocr Pathol       Date:  2000       Impact factor: 4.056

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.